High population immunity from prior infections and vaccinations, combined with robust global surveillance, drives the 92.5% market-implied probability against a new coronavirus pandemic in 2026, as SARS-CoV-2 has transitioned to endemic circulation with mild seasonal waves tracked by CDC wastewater monitoring and WHO variant assessments. Current strains like KP.3.1.1 show no signs of heightened transmissibility or lethality exceeding flu-like baselines, per peer-reviewed genomic surveillance. Trader consensus reflects this stability, bolstered by rapid antiviral deployment capabilities. Realistic challenges include a novel zoonotic spillover event yielding an immune-evading variant or global surveillance lapses enabling unchecked spread, though experts deem these low-probability absent animal reservoir shifts.